Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product Type
3.2. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising incidence and mortality of ovarian cancer.
4.1.1.2. Rising product development activities
4.1.2. Restraints
4.1.2.1. High Cost of advanced therapies
4.1.2.2. XX
4.1.3. Opportunities
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pipeline Analysis
6. By Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
6.1.2. Market Attractiveness Index, By Type
6.2. Epithelial Ovarian Carcinomas*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Germ Cell Tumors
6.4. Stromal Cell Tumors
6.5. Borderline
7. By Drug Class
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
7.1.2. Market Attractiveness Index, By Drug Class
7.2. Chemotherapeutics*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.2.1. Carboplatin
7.2.2.2. Cisplatin
7.2.2.3. Paclitaxel
7.2.2.4. Docetaxel
7.2.2.5. Others
7.3. Targeted Therapies
7.3.1. Monoclonal Antibodies
7.3.2. PARP Inhibitors
7.3.3. Olaparib
7.3.4. Niraparib
7.3.5. Rucaparib
7.4. Others
8. By Region
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.4.1. U.S.
8.2.4.2. Canada
8.2.4.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.4.1. Germany
8.3.4.2. U.K.
8.3.4.3. France
8.3.4.4. Spain
8.3.4.5. Italy
8.3.4.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.4.1. Brazil
8.4.4.2. Argentina
8.4.4.3. Rest of South America
8.5. Asia-Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.4.1. China
8.5.4.2. India
8.5.4.3. Japan
8.5.4.4. South Korea
8.5.4.5. Rest of Asia-Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9. Competitive Landscape
9.1. Competitive Scenario
9.2. Market Positioning/Share Analysis
9.3. Mergers and Acquisitions Analysis
10. Company Profiles
10.1. AbbVie Inc.*
10.1.1. Company Overview
10.1.2. Product Portfolio and Description
10.1.3. Financial Overview
10.1.4. Key Developments
10.2. AstraZeneca.
10.3. Merck & Co., Inc.
10.4. GSK plc.
10.5. pharmaand GmbH.
10.6. Pfizer Inc.
10.7. Amneal Pharmaceuticals LLC.
10.8. Amgen, Inc.
10.9. Sanofi
10.10. Teva Pharmaceuticals USA, Inc.
LIST NOT EXHAUSTIVE
11. Appendix
11.1. About Us and Services
11.2. Contact Us